

Index

Numbers

- ¹⁷⁷LU-PSMA, 84
- ¹⁸F-FDG, 83
- ²²³Ra-dicloride, 90
- ²²⁵AC-PSMA, 87
- ⁶⁸GA-PSMA, 83

A

- Activated kinase, 102
- Adenocarcinoma, 97
- Africa, 7
- Age, 18
- Age-adjusted PSA, 44,45
- Age-standardized rates, 3
- Alcohol, 20
- Alternative strategies, 99
- Androgen deprivation therapy, 61
- Androgen, 35, 102
- Androgenic regulation, 33, 34
- Apoptosis, 37

B

- Bcl-2, 38
- Biomarker, 132
- Bone scan, 52
- BRCA gene mutation, 19
- Bypass pathways, 35, 36

C

- Cancer progression, 61
- Carcinogenesis, 30
- Castrate resistant, 34, 59, 81

- Chemokines, 24
- Chemotherapy, 69
- Choline positron emission tomography, 52
- Clinical evidence, 88
- Clinical trials, 63
- Cognitive targeted biopsy, 50
- Combination therapies, 90
- Combination treatment, 59
- Computed tomography, 51
- Conventional therapies, 82
- Cross-talk, 35
- Current treatment, 61

D

- Diagnostics, 44
- Diet, 21
- Digital rectal examination, 44
- Direct in-bore targeted biopsy, 50
- Docetaxel, 72
- Dose determination, 87
- Dosimetry, 87

E

- Efficacy, 85
- Epidemiology, 1
- Epidermal growth factor, 35
- Ethnicity, 19
- Etiology, 17
- Evaluation criteria, 91

F

- Family history, 18

Fibroblast growth factor, 35
Four kallikrein score, 46
Free and total PSA, 45
Future directions, 97

G

Genetic predisposition, 18
Genome wide association studies, 19
Gleason grading groups, 32, 33

H

Histopathology, 31
Hormone therapy, 99
Hormone-resistance disease, 101
Hormones, 23
Hormone-sensitive disease, 99

I

Imaging, 47, 104
Immunotherapy, 69, 103
Incidence rates, 4
Infection, 24
Inflammation, 24
Insulin-like growth factor, 35

J

Japan, 2, 6, 11

K

Kallikrein, 46
Kinase, 102
Koelis Trinity, 50

L

Lithuania, 10

Localized prostate cancer, 81
Lutetium-177, 82

M

Medications, 22
Metabolic syndrome, 20
Metastatic, 81
Mortality, 3
MRI fusion biopsy, 50
MUCIN 1, 125
Multiparametric magnetic resonance imaging, 48, 51

N

Neuroendocrine features, 102
Nutrition, 21

O

Obesity, 20
Outcomes, 85

P

p53, 113
PARP, 103
Pathogenesis, 29
Patient management, 98
Patient selection, 85
Peptide growth factors, 35
Physical activity, 21
Poly (ADP-ribose) polymerase, 103
Precursor, 31
Progression, 34
Prostate biopsy, 49
Prostate cancer gene 3, 46
Prostate cancer, 1, 17, 29
Prostate health index, 46

Prostate-specific antigen, 44

Prostatic intraepithelial neoplasia, 31

PSA density, 44, 45

PSMA PET, 52

PSMA receptor targeting, 83

PTEN, 36

Q

Quality control, 50

Quality of life, 30, 86

R

Radiation therapy, 68, 100

Radiotherapy, 61

Region-specific incidence, 3

Resistance, 102, 117

Risk calculators, 49

S

Safety, 85

SelectMDX test, 47

Serum tests, 46

Sex, 22

Single agents, 72

Sipuleucel-T, 67

Small molecule inhibitors, 72

Smoking, 20

Staging, 51

STEAP proteins, 139

Surgery, 61

Systemic therapy, 117

T

Targeted radionuclide therapy, 85

Targeting androgen biosynthesis, 70

Taxanes, 67

Theoretical pathways, 34

Theranostics, 81, 104

Therapeutic target, 118, 132

TMPRSS2:ERG, 47

TP53, 116

Translational science, 97

Transrectal ultrasound, 48

Treatment options, 59, 62

Treatment response, 91

Tumor metabolism, 101

Tumor microenvironment, 37

Tumor suppressor gene, 36

U

United Kingdom, 8

Urine tests, 46

V

Vasectomy, 22

W

Worldwide, 11, 12

X

Xerostomia, 88, 105

Y

Year of diagnosis, 4

Z

Z-score, 145

ZZ domain, 133

